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Psoriasis has been associated with increased risk of 
myocardial infarction (MI) in some, but not all, studies. 
This study investigated the risk of MI in patients with 
psoriasis and psoriatic arthritis in Denmark. All resi-
dents aged ≥18 years from 1 January 2008 through 31 
December 2012 were included. Adjusted hazard ratios 
(HRs) did not show an increased risk of MI in patients 
with mild psoriasis (HR 1.02; 95% confidence interval 
(95% CI) 0.96–1.09), whereas the risk was slightly 
increased in patients with severe psoriasis (HR 1.21; 
1.07–1.37). Stratified by age, there was no increased 
risk of MI in any specific age group, regardless of se-
verity. Limited to first-time MI, the risk was increased 
only in patients with severe psoriasis aged <50 years 
(HR 1.52; 1.03–2.25). The same applied to patients 
without psoriatic arthritis (severe psoriasis aged <50 
years; HR 1.74; 1.11–2.72). In analyses restricted to 
patients with psoriatic arthritis, age-specific strata did 
not show any association between psoriatic arthritis 
and MI risk.
Key words: psoriasis; psoriatic arthritis; myocardial infarction; 
cardiovascular disease.
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Psoriasis is one of the most common immune-mediated inflammatory diseases, with an estimated preva-
lence of 2–3% in Europe (1). Approximately 70–80% 
of patients are mildly affected and can be managed with 
topical treatment (2, 3). Psoriatic arthritis is the most 
common comorbidity, affecting approximately 30% of 
patients, and as much as 42% in a Danish study (4). Risk 
factors for cardiovascular disease, such as hypertension, 
dyslipidaemia, diabetes, obesity, smoking, and exces-
sive alcohol intake, occur more frequently in patients 
with psoriasis compared with healthy controls (5, 6). In 
1973, small studies (7, 8) indicated an increased risk of 
cardiovascular disease (CVD) in patients with psoriasis. 
In 2004, Mallbris et al. (9) reported an increased cardio-
vascular mortality in hospitalized younger patients with 
severe psoriasis compared with the general population. 
In contrast, there was no excessive risk in outpatients 
with psoriasis.
The most consistent association between psoriasis and 
CVD is the risk of myocardial infarction (MI), which 
could be increased up to 2-fold in severe psoriasis and 
particularly increased in young individuals according to 
a meta-analysis (10). However, this association has been 
extensively debated due to conflicting data. For example, 
based on data from the United Kingdom General Practice 
Research Datalink between 1987 and 2002, Gelfand et al. 
(11) found a significantly increased risk of MI in patients 
with psoriasis. Interestingly however, another study with 
overlapping cohorts (1994–2009) found somewhat op-
posing results and recent meta-analyses have failed to 
determine whether psoriasis imposes an increased risk of 
CVD independent of the traditional risk factors (12–15). 
In an inception cohort design between 1997 and 2006, 
Ahlehoff et al. (16) reported an increased risk of MI in 
Danish patients with both mild and severe psoriasis. 
However, in that study, the number of hospital visits was 
used to ascertain disease severity, and lack of adjustment 
for important confounding factors may have biased the 
results. While data suggest that the heightened CVD risk 
in psoriasis cannot be explained by the classical cardio-
vascular risk factors alone, the so-called “independent” 
impact of psoriasis on CVD is a topic of ongoing debate 
(17). The aim of the current study was to examine the risk 
of MI in patients with psoriasis and psoriatic arthritis, 
using a more restrictive design, in a nationwide cohort 
of the Danish population between 2008 and 2012. 
MATERIALS AND METHODS
Data sources and study population
Study approval was obtained from the Danish Data Protection 
Agency (reference 2007-58-0015, international reference GEH-
2014-018, I-Suite 02736). Approval from an ethics committee 
is not required for register studies in Denmark (Danish law: 
Lov om videnskabsetisk behandling af sundhedsvidenskabelige 
forskningsprojekter, § 14, stk. 2). The study was conducted in ac-
cordance with the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) recommendations (18). 
In brief, the Danish Civil Registration System assigns a per-
manent and unique 10-digit personal identification number to all 
citizens at birth or immigration, which allows for unambiguous 
linkage across nationwide registers (19). Moreover, the Danish 
Civil Registration System contains information, such as date 
of birth, sex, and vital status, and Statistics Denmark records 
information on tax-reported household income (20). The Danish 
National Patient Register contains information on all inpatient and 
outpatient (ambulatory) hospital contacts since 1978 according to 
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the International Classification of Diseases (ICD) (prior to 1994 
according to the 8th revision (ICD-8) and thereafter the 10th revi-
sion (ICD-10); for administrative reasons ICD-9 was never used 
in Denmark), and hospital treatment interventions, surgeries, and 
hospital administered pharmacotherapy are coded as treatment 
procedure (SKS) codes (21). All pharmacy dispensed prescriptions 
in Denmark are recorded accurately in the Register of Medicinal 
Product Statistics since 1994, and all drugs are classified according 
to the Anatomical Therapeutic Chemical (ATC) classification (22). 
Within 14 days of death, all deaths as causes of deaths are recorded 
in the National Causes of Death Registry (23).
All Danish adults (≥18 years) alive and resident in Denmark on 
1 January 2008 (i.e. the date of study start for all individuals in the 
cohort) were identified. Subjects were followed from study start 
until 31 December 2012, death, migration, or diagnosis of MI, 
whichever came first. Patients were classified as having psoriasis 
if, prior to study start, they had received either a diagnosis of 
psoriasis (ICD-8, 696.10, 696.19 and ICD-10, L40) recorded in 
the DNPR, or if they had been dispensed at least 2 prescriptions 
of topical vitamin D derivatives (ATC code D05AX), which 
is the preferred first-line treatment and is used exclusively for 
psoriasis in Denmark. At least 2 prescriptions were required to 
ensure persistent medical therapy. Patients were classified as 
having severe psoriasis if they received systemic therapy for the 
condition (biological drugs, ciclosporin, psoralen plus ultraviolet 
A (PUVA), retinoids, or methotrexate). Patients with psoriasis 
who had not received systemic therapy were classified as having 
mild psoriasis. This method for identification of psoriasis and clas-
sification of severity has been described and validated elsewhere 
(24). Patients were classified as having psoriatic arthritis if, prior 
to study start, they had received a diagnosis of psoriatic arthritis 
(ICD-8 696.09 and ICD-10 M07.0-M07.3, M09.0). The primary 
endpoint was a diagnosis of MI (ICD-10 I21–I22). The identifica-
tion of MI has been validated previously in the National Patient 
Register with a positive predictive value of 93.6% (25). Fatal MIs 
were collected from the National Causes of Death Registry based 
on death certificates. 
Statistical analysis
Baseline characteristics were described, with means and standard 
deviations for continuous variables and frequencies and percenta-
ges for categorical variables. SAS statistical software version 9.4 
(SAS Institute Inc. Cary, NC, USA) and STATA software version 
13.0 (StataCorp, College Station, TX, USA) were used to sum-
marize incidence rates per 1,000 person-years, and Cox regression 
models were performed to obtain HRs for the risk of MI. These 
HRs were calculated as age- and sex-adjusted, and fully adjusted 
(in which age, sex, socioeconomic status, smoking, alcohol abuse, 
previous CVD, diabetes, hypertension, statin use, and healthcare 
consumption were considered). Included covariates were assessed 
at baseline and up to 5 years prior to study start for comorbidity, 
and up to 6 months prior to study start for medication use. The 
definition of CVD included acute coronary syndrome comprising 
both MI and unstable angina pectoris, angina pectoris, cerebrovas-
cular event or stroke, transient ischaemic attack, peripheral artery 
disease and revascularization procedures, including coronary 
artery bypass surgery, percutaneous coronary intervention and 
percutaneous transluminal coronary angioplasty. Diabetes was 
defined by either a hospital diagnosis (in- or outpatient), or use of 
glucose-lowering drugs. Collection of proxy data on hypertension, 
smoking, and alcohol abuse has been described elsewhere (24, 
26, 27). An index of socioeconomic status (standardized by age) 
between 0 (lowest group) and 4 (highest group) was calculated 
based on the mean gross annual income during a 5-year period 
before study inclusion. Sensitivity analyses were performed in 
which patients with a history of MI prior to study start were 
excluded, in order to assess the risk of first-time MI. In addition, 
the primary analysis was repeated with stratification based on age 
(< 50, 50–< 60, 60–< 70,  ≥ 70 years). Sensitivity analyses were per-
formed, in which comorbidity and medication use were included 
as time-dependent variables that were updated during follow-up. 
Model assumptions, including linearity of continuous variables 
and the proportional hazards assumption, were tested and found 
to be valid. Two-tailed p-values < 0.05 were considered statisti-
cally significant, and results were reported with 95% confidence 
intervals (CIs), where applicable. Throughout this paper the term 
“increased risk” refers to a statistically significant increased risk, 
unless explicitly stated otherwise.
RESULTS
The study comprised a total of 4,361,688 Danish re-
sidents, aged ≥ 18 years on 1 January 2008. Of these, 
49,646 and 11,957 patients were classified as having 
mild and severe psoriasis, respectively, including 8,149 
patients with psoriatic arthritis. Consistently across the 
study groups, there was a slight female predominance, 
and the mean age ranged between 48.6 and 56.7 years 
(Table I).
Table I. Baseline characteristics of the study population
General population
(n = 4,300,085)
With or without psoriatic arthritis Cutaneous psoriasis only
Psoriatic arthritis
(n = 8,149)
Mild psoriasis
(n = 49,646)
Severe psoriasis
(n = 11,957)
Mild psoriasis
(n = 46,085)
Severe psoriasis
(n = 7,369)
Age, years, mean (standard deviation) 48.6 (18.0) 54.6 (16.3) 55.7 (14.9) 54.5 (16.4) 56.7 (15.5) 54.6 (14.1)
Sex, n (%)
   Women 2,184,102 (50.8) 25,563 (51.5) 6,256 (52.3) 23,522 (51.0) 3,747 (50.9) 4,550 (55.8)
   Men 2,115,983 (49.2) 24,083 (48.5) 5,701 (47.7) 22,563 (49.0) 3,622 (49.1) 3,599 (44.2)
Socioeconomic status, n (%)
   Lowest 864,785 (20.1) 6,304 (12.7) 1,247 (10.4) 5,904 (12.8) 878 (11.9) 769 (9.4)
   Below average 857,899 (20.0) 11,300 (22.8) 3,139 (26.3) 10,391 (22.6) 1,977 (26.8) 2,071 (25.4)
   Average 858,842 (20.0) 10,582 (21.3) 2,912 (24.4) 9,705 (21.1) 1,706 (23.2) 2,083 (25.6)
   Above average 859,895 (20.0) 10,010 (20.2) 2,436 (20.4) 9,326 (20.2) 1,441 (19.6) 1,679 (20.6)
   Highest 858,664 (20.0) 11,450 (23.1) 2,223 (18.6) 10,759 (23.4) 1,367 (18.6) 1,547 (19.0)
Smoking, n (%) 423,021 (9.8) 7,670 (15.5) 2,246 (18.8) 7,090 (15.4) 1,501 (20.4) 1,325 (16.3)
Alcohol abuse, n (%) 180,662 (4.2) 3,084 (6.2) 788 (6.6) 2,866 (6.2) 542 (7.4) 464 (5.7)
Cardiovascular disease, n (%) 370,831 (8.6) 7,019 (14.1) 1,949 (16.3) 6,476 (14.1) 1,233 (16.7) 1,259 (15.5)
Diabetes, n (%) 153,969 (3.6) 3,278 (6.6) 947 (7.9) 3,053 (6.6) 588 (8.0) 584 (7.2)
Hypertension, n (%) 516,585 (12.0) 9,649 (19.4) 2,485 (20.8) 8,884 (19.3) 1,525 (20.7) 1,725 (21.2)
Cholesterol-lowering drugs, n (%) 392,237 (9.1) 7,534 (15.2) 1,881 (15.7) 6,862 (15.1) 1,154 (15.7) 1,299 (15.9)
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During follow-up, a total of 53,272 subjects from 
the general population were diagnosed with an MI, of 
which 44,129 were first-time MIs. Among patients with 
mild and severe psoriasis, there were 896 (first-time MI, 
n = 723) and 263 (first-time MI, n = 213) cases of MI, of 
which 158 (first-time MI, n = 128) occurred in patients 
with psoriatic arthritis. The corresponding incidence 
rates par 1,000 person-years of exposure are shown in 
Table II. 
Risk of myocardial infarction in patients with either 
psoriasis or psoriatic arthritis
Adjusted analyses (i.e. adjusted for age, sex, socio-
economic status, smoking, alcohol abuse, previous 
CVD, diabetes, hypertension, statin use, and healthcare 
consumption) did not show an increased risk of MI in 
patients with mild psoriasis (hazard ratio (HR) 1.02; 
95% confidence interval (95% CI) 0.96–1.09), whereas 
the risk was slightly increased in patients with severe 
psoriasis (HR 1.21; 95% CI 1.07–1.37) (Table III). 
Stratified by age, there was no increased risk of MI in 
any specific age group, for either mild or severe psoriasis 
(Table IV). When analyses were limited to patients with 
first-time MI, the overall adjusted HRs were 1.03 (95% 
CI 0.96–1.11) and 1.21 (95% CI 1.05–1.39) for mild 
and severe psoriasis, respectively. When the analyses for 
first-time MI risk were stratified by age, the risk was only 
significantly increased in patients with severe psoriasis 
aged <50 years (HR 1.52; 95% CI 1.03–2.25).
Risk of myocardial infarction in patients with cutaneous 
psoriasis only
In analysis limited to patients without psoriatic arthritis, 
the overall HR of MI was 1.01 (95% CI 0.94–1.08) for 
mild, and 1.19 (95% CI 1.03–1.39) for severe psoriasis. 
In age-specific strata, the risk was only significantly 
increased among patients aged < 50 years with severe 
psoriasis (HR 1.74; 95% CI 1.11–2.72). For first-time 
MI, there was no increased risk associated with either 
mild or severe psoriasis. However, in patients aged < 50 
Table II. Summary of number of events, follow-up time, and incidence rates per 1,000 person-years (PY)
General 
population
Including psoriatic arthritis Cutaneous psoriasis only
Psoriatic arthritisMild psoriasis Severe psoriasis Mild psoriasis Severe psoriasis
Any myocardial infarction
   Follow-up time, years 20,539,481 233,806 56,212 216,917 34,269 38,832
   Number of events 53,272 896 263 826 175 158
   Incidence rate/1,000 PY 2.59 3.83 4.68 3.81 5.11 4.07
   95% confidence interval 2.57–2.62 3.59–4.09 4.15–5.28 3.56–4.08 4.40–5.92 3.49–4.76
First-time myocardial infarction
   Follow-up time, years 20,193,191 227,119 54,467 210,726 33,185 37,675
   Number of events 44,129 723 213 670 138 128
   Incidence rate/1,000 PY 2.19 3.18 3.91 3.18 4.16 3.40
   95% confidence interval 2.17–2.21 2.96–3.42 3.42–4.47 2.95–3.43 3.52–4.91 2.86–4.04
Table III. Risk of myocardial infarction in patients with psoriasis 
and psoriatic arthritis
 
Any myocardial 
infarction
 
First-time myocardial 
infarction
Adjusted HR 
(95% CI) p-value
Adjusted HR 
(95% CI) p-value
Any psoriasis
   Mild psoriasis 1.02 (0.96–1.09) 0.5209 1.03 (0.96–1.11) 0.3646
   Severe psoriasis 1.21 (1.07–1.37) 0.0023 1.21 (1.05–1.39) 0.0065
Cutaneous psoriasis only
   Mild psoriasis 1.01 (0.94–1.08) 0.7881 1.03 (0.95–1.11) 0.4790
   Severe psoriasis 1.19 (1.03–1.39) 0.0221 1.15 (0.97–1.37) 0.1028
Joint disease
   Psoriatic arthritis 1.22 (1.05–1.43) 0.0116 1.23 (1.04–1.47) 0.0177
CI: confidence interval; HR: hazard ratio: adjusted for age, sex socioeconomic 
status, previous cardiovascular disease (CVD), diabetes, alcohol, smoking, 
hypertension, cholesterol-lowering drug use, and healthcare consumption.
Table IV. Risk of myocardial infarction in patients with psoriasis 
and psoriatic arthritis, age stratified 
 
Any myocardial 
infarction
 
First-time myocardial 
infarction
Adjusted HR 
(95% CI) p-value
Adjusted HR 
(95% CI) p-value
Any psoriasis
Mild psoriasis
  < 50 years 1.19 (0.96–1.49) 0.1133 1.19 (0.95–1.50) 0.1344
  50–< 60 years 0.96 (0.81–1.14) 0.6514 0.95 (0.79–1.14) 0.5908
  60–< 70 years 1.05 (0.93–1.19) 0.4213 1.09 (0.95–1.25) 0.2287
  ≥ 70 years 1.00 (0.91–1.10) 0.9486 1.01 (0.90–1.12) 0.9020
Severe psoriasis
  < 50 years 1.41 (0.97–2.06) 0.0712 1.52 (1.03–2.25) 0.0346
  50–< 60 years 1.20 (0.90–1.59) 0.2264 1.16 (0.85–1.59) 0.3454
  60–70 years 1.09 (0.86–1.37) 0.4891 1.08 (0.83–1.40) 0.5779
  ≥ 70 years 1.20 (0.99–1.44) 0.0602 1.18 (0.95–1.47) 0.1247
Cutaneous psoriasis only
Mild psoriasis
  < 50 years 1.18 (0.93–1.48) 0.1665 1.16 (0.91–1.49) 0.2203
  50–< 60 years 0.95 (0.79–1.14) 0.5778 0.94 (0.77–1.14) 0.5189
  60–< 70 years 1.05 (0.92–1.19) 0.5075 1.07 (0.93–1.23) 0.3572
  ≥ 70 years 1.00 (0.90–1.10) 0.8989 1.02 (0.91–1.14) 0.7480
Severe psoriasis
  < 50 years 1.74 (1.11–2.72) 0.0160 1.90 (1.20–3.02) 0.0064
  50–< 60 years 1.06 (0.71–1.58) 0.7764 0.96 (0.62–1.50) 0.8709
  60–< 70 years 1.14 (0.85–1.51) 0.3710 1.05 (0.76–1.45) 0.7693
  ≥ 70 years 1.18 (0.95–1.47) 0.1439 1.15 (0.89–1.48) 0.2781
Joint disease
Psoriatic arthritis
  < 50 years 1.11 (0.68–1.83) 0.6706 1.19 (0.71–1.99) 0.5014
  50–< 60 years 1.24 (0.89–1.72) 0.2011 1.28 (0.90–1.81) 0.1705
  60–< 70 years 1.05 (0.78–1.42) 0.7381 1.21 (0.88–1.65) 0.2447
  ≥ 70 years 1.22 (0.95–1.56) 0.1243 1.06 (0.78–1.44) 0.6993
CI: confidence interval; HR: hazard ratio: adjusted for age, sex socioeconomic 
status, previous cardiovascular disease (CVD), diabetes, alcohol, smoking, 
hypertension, cholesterol-lowering drug use, and healthcare consumption.
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years with severe psoriasis we did find an increased 
risk (HR 1.90; 95% CI 1.20–3.02), as shown in Table 
IV and Fig. 1. 
Risk of myocardial infarction in patients with psoriatic 
arthritis
When analyses were limited to patients with psoriatic 
arthritis, the overall risk of MI was slightly increased 
(HR 1.22; 95% CI 1.05–1.43), as was the risk of first-
time MI (HR 1.23; 95% CI 1.04–1.47). However, in 
age-specific strata, there was no association between 
psoriatic arthritis and risk of MI, including first-time MI 
(Table IV and Fig. 1).
In sensitivity analyses, where covariates were adjusted 
during follow-up, there were no significant differences 
compared with our primary analyses (data not shown). 
Detailed data on model coefficients are available in the 
supplementary materials.
DISCUSSION
In this nationwide cohort study of the Danish adult popu-
lation between 2008 and 2012, we found a slightly (yet 
statistically significant) increased risk of MI in patients 
with psoriasis and psoriatic arthritis. Notably, however, 
the risk was increased only among patients < 50 years 
of age, and predominantly present in patients without 
psoriatic arthritis. 
Previously, using data from the UK, Gelfand et al. (11) 
demonstrated an age- and psoriasis severity-dependent 
increased risk of MI where the adjusted relative risk 
(RR) in young patients (aged 30 years) was 1.29 (95% 
CI 1.14–1.46) for mild, and 3.10 (95% CI 1.98–4.86) 
for severe psoriasis, respectively. Conversely, for older 
patients (aged 60 years), the adjusted RR was 1.08 (95% 
CI 1.03–1.13) for mild, and 1.36 (95% CI 1.13–1.64) for 
severe psoriasis, respectively. On the other hand, using 
the same data source Parisi and colleagues (12) did not 
show a significantly increased risk of major adverse 
cardiovascular events (MACE) in patients with severe 
psoriasis (adjusted HR 1.28; 95% CI 0.96–1.69). How-
ever, in a subanalysis excluding patients with psoriatic 
arthritis, the risk of MACE was significantly increased 
(adjusted HR 1.46; 95% CI 1.11–1.92) in patients with 
severe psoriasis. One previous Danish study using the 
same register data as here (16) found an increased risk of 
first-time MI associated with mild psoriasis (adjusted RR 
1.22; 95% CI 1.12–1.33), and severe psoriasis (adjusted 
RR 1.45, 95% CI 1.10–1.90), respectively. Notably, 
when stratified by age, the risk of MI in patients with 
mild disease was increased only in patients > 70 years of 
age (adjusted RR 1.30; 95% CI 1.16–1.45), whereas the 
risk in patients with severe psoriasis was significantly 
increased only in patients ≤ 50 years of age (adjusted 
RR 2.32; 95% CI 1.19–4.50). The apparent discrepancy 
between the results here and the previous findings may 
be due to the applied definition of disease severity. As in 
the studies by Gelfand et al. (11) and Parisi et al. (12), we 
used systemic anti-psoriatic therapy to ascertain disease 
severity; a method which we have previously validated 
(24). Conversely, in the previous study from the Danish 
3
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Fig. 1. Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis, age stratified. (A) Risk of any myocardial infarction in 
patients with mild and severe psoriasis, regardless of presence or absence of psoriatic arthritis. (B) Risk of first-time myocardial infarction in patients with 
mild and severe psoriasis, regardless of presence or absence of psoriatic arthritis. (C) Risk of any myocardial infarction in patients with mild and severe 
psoriasis (cutaneous only), and psoriatic arthritis, respectively. (D) Risk of first-time myocardial infarction in patients with mild and severe psoriasis 
(cutaneous only), and psoriatic arthritis, respectively.
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databases (16), patients were considered to have mild 
disease until the time of their third hospital visit due to 
psoriasis, whereby patients in private dermatology clinics 
were automatically considered to have mild disease, as 
were patients who were seen only twice in a hospital set-
ting at the time of their MI. We believe that this strategy 
may introduce bias in the analyses, since patients with 
severe psoriasis are treated in secondary clinics in rural 
parts of Denmark. 
The link between psoriasis and atherosclerosis has 
been highlighted by the fact that both conditions are 
characterized by T-helper (Th)1 and Th17 activation 
and reduced T-regulatory cell function, with striking 
similarities in their immunoinflammatory mechanisms 
(28). Indeed, inflammation is important in atherogenesis 
and atherosclerosis (29, 30), and systemic inflamma-
tion has been put forward as a potential explanation for 
the observed increased prevalence and risk of CVD in 
patients with psoriasis. However, patients with psoria-
sis also tend to exercise less (31) and smoke more than 
the general population (32), and the level of alcohol 
consumption is correlated with the extent of psoriasis 
(33). In addition, presence of depression also appears 
to significantly affect the CVD risk in patients with 
psoriasis (34). While our models were adjusted for fac-
tors such as smoking and alcohol abuse, these potential 
confounders were unaccounted for in the previous study 
from Denmark (16). Nevertheless, important limitations 
apply to the interpretation of the present results. The 
algorithm for identification of smoking history may 
lead to an underestimation of smoking in this cohort, 
whereby the increased MI risk in our study may partly be 
explained by residual confounding. We identified patients 
with psoriasis either by a diagnosis of psoriasis or by 
claimed prescriptions for topical vitamin D analogues 
(Tables SI–SIV1, Fig. S11). While the National Patient 
Register contains inpatient and outpatient diagnoses for 
all individuals seen in hospital clinics, patients seen, 
for example, by dermatologists in private clinics would 
not be captured by such diagnostic codes. However, use 
of topical vitamin D analogues allowed identification 
of patients seen outside a hospital setting. Indeed, in 
Denmark, these agents are the preferred anti-psoriatic 
therapy by general practitioners and dermatologists (35). 
Moreover, use of the above-mentioned method allowed 
for direct comparison between our study and the study 
by Ahlehoff et al. (16), since the both studies used the 
same definition of psoriasis. Due to the observational 
nature of our study, we cannot claim a causal link. Also, 
the apparent increased prevalence of CVD in psoriasis 
may be partially attributed to the high prevalence of 
metabolic abnormalities, for which obesity, lifestyle, and 
genetics may provide the link (36, 37). Indeed, patients 
with psoriasis tend to be heavier than non-psoriatic indi-
viduals, and a causal link between obesity and psoriasis 
has been discussed (36). In addition, data suggest that 
the “independent” effect of psoriasis on the risk of CVD 
is virtually eliminated when the results are adjusted for 
a family history of CVD (37). We lacked information 
on body weight and family history, and it is likely that 
at least some of the observed MI risk in our study was 
due to residual confounding owing to obesity and other 
lifestyle factors. The present study applied a prevalent 
rather than incident disease design. This approach was 
chosen because the exact onset of disease may by im-
precise, since patients may have had psoriasis for many 
years before seeking medical attention. The strengths of 
a prevalent vs. an incident disease design for psoriasis 
research has been described in detail elsewhere (17). 
Lastly, certain anti-psoriatic pharmacotherapies may also 
increase the risk of MI (38).
In conclusion, we found a slightly increased risk of MI 
in patients with psoriasis and psoriatic arthritis. Notably, 
however, the risk was increased only among patients 
< 50 years of age, and predominantly present in patients 
without psoriatic arthritis. Therefore, it remains unclear 
if psoriasis is an independent risk factor for MI.
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